Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers for prediction of CRSwNP patient responses to mepolizumab
2023-508069-34-01Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of mepolizumab in chronic rhinosinusitis with nasal polyps (CRSwNP) (3 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Identification of cell/molecular biomarkers correlated with individual patients’ responses, Identification of immunological mechanisms behind responses to mepolizumab and 1 more. Planned start Jun 2024; status: authorised.
02
Drugs
mepolizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on 2023-508069-34-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508069-34-01.